Most drug target identification strategies result in a list of target genes. While there are a number of basic challenges that are shared by all drug target mining approaches due to the complexity of biological signaling networks, non-nucleic acid approaches require particularly detailed information about molecular functions, pathways and phenotypes of the gene products.
This webinar discusses the complexities of post-translational modification, recycling/degradation, and alternative splicing patterns of proteins affect signaling networks in ways that can impact the selection of drug targets. Examples of proteins involved in alzheimers, epilepsy and other diseases are used to demonstrate the use of biological databases describing inherited mutations (HGMD®) and the molecular mechanisms of signaling events (PROTEOME™) make it easier to prioritize and filter potential drug targets than relying on literature searches alone.
Learn how to:
- Identify known mutations that affect sites of post-translational modification
- Visualize how key post-translational events affect characterized pathways
- Identify proteins which participate in multiple signaling networks